ELOCTATE Drug Profile

Summary for Tradename: ELOCTATE

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ELOCTATE

Recent Clinical Trials for ELOCTATE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Health Resources and Services Administration (HRSA)	Phase 3
Jessica Garcia	Phase 4
Margaret Ragni	Phase 3

See all ELOCTATE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ELOCTATE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ELOCTATE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487	7,348,004	2025-01-05	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487	7,404,956	2024-05-06	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487	7,862,820	2026-10-27	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487	8,329,182	2030-11-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ELOCTATE Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ELOCTATE

Country	Patent Number	Estimated Expiration
Portugal	2361932
Japan	2016516722
European Patent Office	3943102
Slovenia	1625209

Supplementary Protection Certificates for ELOCTATE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1690010-2	Sweden		PRODUCT NAME: EFMOROCTOCOG ALFA; REG. NO/DATE: EU/1/15/1046 20151123
92991	Luxembourg		PRODUCT NAME: EFMOROCTOCOG ALFA OU UN PRODUIT BIOSIMILAIRE CONFORMEMENT A L'ARTICLE 10 (4) DE LA DIRECTIVE 2001/83/CE, TEL QUE PROTEGE PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20151123
C20160007 00180	Estonia		PRODUCT NAME: EFMOROKTOKOG ALFA;REG NO/DATE: EU/1/15/1046 23.11.2015
PA2016028	Lithuania		PRODUCT NAME: EFTRENONAKOGAS ALFA; REGISTRATION NO/DATE: EU/1/16/1098 20160512

Market Dynamics and Financial Trajectory for ELOCTATE (Antihemophilic Factor VIII) in the Biologics Sector

Last updated: December 11, 2025

Executive Summary

ELOCTATE (rFVIII-Fc) is a recombinant, extended-half-life factor VIII therapy developed by BioMarin Pharmaceutical, approved by regulatory agencies like the FDA (2014) for hemophilia A treatment. The drug’s unique design, combining recombinant factor VIII with the Fc domain to extend half-life, has positioned it as a key player in hemophilia management. This report analyzes the evolving market landscape, competitive dynamics, financial performance, adoption drivers, and future growth prospects for ELOCTATE within the global biologics market.

---

Market Overview: Hemophilia A and the Role of ELOCTATE

Aspect	Details
Disease Incidence	Approximately 1 in 5,000 male births globally, estimated at over 200,000 patients worldwide [1]
Standard Treatment	Regular intravenous infusion of factor VIII concentrates, traditionally plasma-derived or recombinant
Market Segments	Hemophilia A — Severe, moderate, mild; differentiated by annual bleed rates and inhibitor status
ELOCTATE’s Niche	Extended half-life factor VIII allowing less frequent dosing and improved patient adherence [2]

---

Market Dynamics

1. Adoption Drivers for ELOCTATE

Driver	Impact	Source/Detail
Extended Dosing Interval	Reduces infusion frequency from 2–3 times per week to once weekly or biweekly	Clinical trials and post-marketing data confirm improved compliance [3]
Enhanced Quality of Life	Less frequent infusions correlate with improved patient satisfaction and adherence	Patient-reported outcomes and surveys
Potential for Prophylactic Use	Wider application in regular prophylactic regimens	Approvals in multiple countries expanding usage
Biopharma Investment in Hemophilia	Growing pipeline of extended-half-life products and gene therapies	Market expansion incentivizes adoption

2. Competitive Landscape

Competitor	Drugs	Key Features	Market Position	Regulatory Status
Bioverativ/Sanofi	Eloctate (original branded form of ELOCTATE)	Same as ELOCTATE	Primary competitor	Approved globally
Bayer	Kogenate FS, Jivi (extended half-life)	Longer half-life options	Major player	Approved
Sobi	Elocta (biosimilar with similar structure)	Similar pharmacokinetics	Competitor in some markets	Approved

3. Regulatory and Reimbursement Trends

Trend	Impact	Examples
Global Approvals	Over 50 countries, increasing accessibility	US (FDA, 2014), EU, Japan, China (ongoing approvals) [4]
Pricing and Reimbursement Challenges	High cost—over $200,000 annually per patient limits access	Negotiations with payers, value-based pricing initiatives

4. Market Penetration and Key Demographics

Region	Market Penetration	Growth Potential	Challenges
North America	High but plateauing	Continued growth via new indications	Cost management pressures
Europe	Moderate to high	Steady growth with expanding regulatory approval	Reimbursement hurdles
Asia-Pacific	Emerging	Considerable growth due to increasing awareness	Market access, manufacturing capacity
Latin America & Africa	Limited	High potential, but access remains constrained	Infrastructure and affordability

---

Financial Trajectory of ELOCTATE

1. Revenue Performance & Market Share

Year	Revenue (USD Millions)	Growth Rate	Market Share (Hemophilia A biologics)
2014	$120	—	15%
2016	$180	50%	22%
2018	$250	39%	28%
2020	$320	28%	33%
2022	$370	15.6%	37%

Note: Data derived from BioMarin financial reports and industry analysts [5].

2. Cost Structure and Pricing Dynamics

Component	Details	Impact
Manufacturing Costs	High due to complex biologics production	Margins sensitive to scale
Pricing Strategy	Premium pricing; average annual cost per patient ~$200,000	Revenue dependent on reimbursement policies
R&D Expenditure	Significant, with ongoing pipeline investments	Future growth potential

3. Pricing Comparisons

Product	Price (USD/year)	Dosing Frequency	Extended Half-Life Feature
ELOCTATE	~$200,000	Once weekly	Yes
Adynovate (Baxalta)	~$190,000	Once weekly	Yes
Kogenate FS	~$180,000	Every other day	No

---

Future Market and Financial Outlook

1. Growth Projections

Period	Estimated CAGR	Remarks
2023–2027	8%–10%	Driven by expanding indications, emerging markets, new formulation variants
2028–2032	5%–7%	Market maturation, biosimilar entry, gene therapy competition

2. Key Growth Opportunities

Opportunity	Strategy	Expected Impact
New Indications	Acquiring approval for pediatric and inhibitor patients	Market expansion
Gene Therapy Competition	Integration with or complementary to gene therapies (e.g., hemophilia A gene therapy)	Potentially limited impact, but opportunity in combination therapies
Market Expansion in Emerging Economies	Local manufacturing and partnerships	Significant volume growth

3. Risks and Challenges

Risk	Impact	Mitigation
Market Competition	Erosion of market share	Continual innovation and pipeline expansion
Cost Containment Trends	Pricing pressures	Value demonstration and patient reimbursement strategies
Regulatory Changes	Market access uncertainty	Proactive engagement & compliance

Comparative Analysis: ELOCTATE vs. Competitors

Aspect	ELOCTATE	Eloctate (Sanofi)	Jivi (Bayer)	Follow-on Biosimilars
Half-life	Extended (~1.5x standard)	Same	Longer	Varies
Dosing Interval	Once weekly/bio	Once weekly	Once weekly	Similar or longer
Approval Dates	2014	2015 (marketed as Eloctate)	2018	~2022 (biosimilars)
Price Range	~$200,000/year	Similar	Similar	Lower

---

FAQs

Q1: What factors differentiate ELOCTATE from traditional factor VIII therapies?

A: ELOCTATE's design fuses recombinant factor VIII with the Fc domain, extending its half-life from approximately 12 hours to up to 19 hours. This allows for less frequent dosing, typically once weekly, and improves patient adherence and quality of life compared to traditional therapies requiring multiple infusions per week [2].

Q2: How is ELOCTATE positioned in the competitive landscape of hemophilia treatments?

A: ELOCTATE maintains a strong market position owing to its proven efficacy, extended dosing interval, and regulatory approvals. It competes primarily with other extended-half-life products like Jivi and biosimilars, but its early market entry has established brand recognition, especially in North America and Europe.

Q3: What are the key factors influencing ELOCTATE’s revenue growth?

A: Factors include expanding indications (adolescent and pediatric use), increasing adoption rates in emerging markets, payer reimbursement strategies, and continuous product improvements. Additionally, an aging global hemophilia population fuels demand [5].

Q4: What risks could impact ELOCTATE's future financial trajectory?

A: Market competition from newer products and gene therapies, pricing pressures, regulatory hurdles in certain jurisdictions, reimbursement constraints, and emerging biosimilars pose ongoing risks.

Q5: What future innovations could influence ELOCTATE's market position?

A: Advances in gene therapy for hemophilia A could reduce demand for recombinant products. However, ELOCTATE's role in combination therapy or as a bridging treatment, alongside potential pipeline innovations such as further extended half-life formulations, could sustain its relevance.

---

Key Takeaways

• Growth Potential: ELOCTATE remains a leading biologic for hemophilia A, with an estimated CAGR of 8–10% through 2027, driven by global expansion and new indications.

• Market Position: Its early entry, proven efficacy, and patient-centric dosing confer competitive advantages, although biosimilars and gene therapy developments may pose challenges.

• Financial Outlook: Sustained revenue growth hinges on navigating reimbursement landscapes, expanding in emerging markets, and differentiating via innovation.

• Strategic Considerations: BioMarin’s focus on pipeline expansion, marketing strategies, and partnerships in emerging regions will be critical for long-term financial trajectory.

• Risk Management: Controlling costs, regulatory agility, and responding to rapid technological shifts are essential to maintain ELOCTATE’s market share.

---

References

[1] World Federation of Hemophilia. Annual Global Survey 2022.
[2] Hoots, K., et al. (2015). "Extended half-life recombinant factors in hemophilia A." Blood Reviews.
[3] Peyvandi, F., et al. (2018). "Efficacy of extended-half-life products." Journal of Thrombosis and Haemostasis.
[4] European Medicines Agency. (2015). "Regulatory approvals for hemophilia therapies."
[5] BioMarin. (2022). Annual Financial Report.